Business
Collaboration with King's College London
Collaboration with King's College London.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 1563Z Evgen Pharma PLC 13 December 2017 \n\n \n\n\n\n\nFor immediate release\n\n\n13 December 2017\n\n\n\n\n \n\n\n \n\n\n\n\n \n \n \n \n \nEvgen Pharma plc \n (\"Evgen Pharma\" or \"the Company\")\n \nCollaboration with King's College in Ischaemic Stroke\n \nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce a collaboration with King's College London (\"King's\") to advance SFX-01, the Company's lead product candidate, towards the clinic as a therapy for ischaemic stroke.\n \nIn a programme of work funded by the British Heart Foundation (\"BHF\"), scientists at King's have previously shown the potential of sulforaphane - the active principle in SFX-01 - to minimise brain injury and subsequent motor deficits in highly reproducible models of ischaemic stroke. \n \nThe initial aim of the collaboration is to test SFX-01 at various doses in the aforementioned models with a view to building a clinical-trial enabling data package. This part of the work programme is being seed-funded by Evgen Pharma and will take approximately nine months to complete.\n \nIf the data looks promising, Evgen Pharma will provide quantities of SFX-01 to support a potential grant-funded clinical trial to be led by King's. Under the terms of the collaboration agreement, the Company will have first refusal to an exclusive licence to all data and new intellectual property from such a trial on fair commercial terms to be negotiated and duly recognising the respective investments of all parties.\n \nEvgen Pharma is already progressing SFX-01 in two Phase II trials, for advanced breast cancer and a rare type of stroke called subarachnoid haemorrhage.\n \nGiovanni Mann, Professor of Vascular Physiology at King's, commented:\n\"We are delighted to be collaborating with Evgen Pharma on this exciting project. We have previously had grant support from the British Heart Foundation to test sulforaphane in laboratory models of ischaemic stroke and produced compelling data. However, sulforaphane is not a practical pharmaceutical product as it is highly unstable. With SFX-01, a stable pharmaceutical version of sulforaphane, we are now able to consider a clin...